Early prediction of blonanserin response in Japanese patients with schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 1861-1866

  Kishi, Taro ^a   Matsuda, Yuki ^a   Fujita, Kiyoshi ^b,c   Iwata, Nakao ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Okehazama Hospital   (Japan)

^c Neuroscience Research Center   (Japan)

Author keywords

Antipsychotic; Efficacy; Safety

Indexed keywords

BLONANSERIN;

ADULT; ADVERSE OUTCOME; AGED; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; JAPANESE (PEOPLE); MALE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; SCHIZOPHRENIA; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; YOUNG ADULT;

EID: 84908218140     PISSN: None     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S70227     Document Type: Article

References (20)

1. Tenjin T, Miyamoto S, Ninomiya Y, et al. Profile of blonanserin for the treatment of schizophrenia. Neuropsychiatr Dis Treat. 2013;9:587–594.
2. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10(1):79–104.
3. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
4. Kishi T, Matsuda Y, Nakamura H, Iwata N. Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials. J Psychiatr Res. 2013;47(2):149–154.
5. Kishi T, Matsuda Y, Iwata N. Cardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2014;9(2): e88049.
6. Park JI, Cho DH, Hahn SW, et al. The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis. Int Clin Psychopharmacol. 2014;29(2):77–85.
7. Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry. 1995;152(12): 1724–1729.
8. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302(16):1765–1773.
9. Liu CC, Chien YL, Hsieh MH, Hwang TJ, Hwu HG, Liu CM. Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study. J Clin Psychopharmacol. 2013;33(1):18–23.
10. Gaebel W, Riesbeck M, Wölwer W, et al. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2007;68(11):1763–1774.
11. Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618): 1085–1097.
12. Correll CU, Malhotra AK, Kaushik S, McMeniman M, Kane JM. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry. 2003;160(11):2063–2065.
13. Leucht S, Busch R, Kissling W, Kane JM. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry. 2007;68(3):352–360.
14. Leucht S, Zhao J. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program. J Psychopharmacol. 2014;28(4):387–394.
15. Leucht S, Shamsi SA, Busch R, Kissling W, Kane JM. Predicting antipsychotic drug response–replication and extension to six weeks in an international olanzapine study. Schizophr Res. 2008;101(1–3):312–319.
16. Miura S. Clinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with riperidone. Jpn J Clin Psychopharmacol. 2008;11:297–314.
17. Murasaki M. Clinical evaluation of blonanserin for schizophrenia: a double-blind trial comparing blonanserin with haloperidol. Jpn J Clin Psychopharmacol. 2007;10:2059–2079.
18. Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs. 2009;23(7):615–625.
19. Yang J, Bahk WM, Cho HS, et al. Efficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol. 2010;33(4):169–175.
20. Mallinckrodt CH, Kaiser CJ, Watkin JG, Molenberghs G, Carroll RJ. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. Clin Trials. 2004;1(6):477–489.